Registration Deadline:
Vanderbilt Contact:
Explore other Industry Opportunities:
Overview
- Seeking technologies to overcome limitations of current IBV vaccines
- Focus on solutions that allow rapid updates to effectively address emerging strains
- Interest in both next-generation vaccines and enabling technologies
- Target protection level of ≥60% across IBV variants
Priority Areas
- RNA vaccines
- Subunit vaccines
- High-yield heterologous expression platforms
- Adjuvants with depot effect safe for in ovo administration
- Delivery systems and formulations for drinking water, gel, spray, or in ovo vaccination
Eligibility & Requirements
- Must demonstrate potential to induce protective immunity across IBV variants
- Must provide clear rationale or pathway for scalable, high-volume production
- Must include preliminary data supporting safety in poultry and/or embryos
- Technology Readiness Levels (TRL) 3-9 are acceptable
- Out of scope: Live attenuated vaccines and conventional inactivated vaccines
Nice-to-Have Features
- Compatibility or adaptability to mass administration (spray, drinking water, or in ovo delivery)
- Inclusion of adjuvant with depot effect
Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.